Zoetis (ZTS) Other Non-Current Liabilities (2012 - 2026)
Zoetis (ZTS) reported Other Non-Current Liabilities of $281.0 million for Q1 2026, up 27.73% year-over-year from $220.0 million in Q1 2025, and up 1.81% quarter-over-quarter from $276.0 million in Q4 2025.
Zoetis (ZTS) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Other Non-Current Liabilities data on file, last reported at $281.0 million in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $281.0 million, up 27.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $281.0 million (up 27.73% YoY), and the FY2025 annual result was $276.0 million, up 24.32% from the prior year.
- Other Non-Current Liabilities improved to $281.0 million in Q1 2026 per ZTS's latest filing, from $276.0 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $281.0 million in Q1 2026 and troughed at $216.0 million in Q1 2023.
- A 5-year average of $251.2 million and a median of $258.0 million in 2022 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities gained 28.24% in 2024, then retreated 20.58% in 2025.
- A 5-year view of Other Non-Current Liabilities shows it stood at $258.0 million in 2022, then climbed by 5.04% to $271.0 million in 2023, then dropped by 18.08% to $222.0 million in 2024, then grew by 24.32% to $276.0 million in 2025, then rose by 1.81% to $281.0 million in 2026.
- Business Quant data shows ZTS's Other Non-Current Liabilities at $281.0 million in Q1 2026, $276.0 million in Q4 2025, and $264.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 281.00 Mn |
| Dec 31, 2025 | 276.00 Mn |
| Sep 30, 2025 | 264.00 Mn |
| Jun 30, 2025 | 274.00 Mn |
| Mar 31, 2025 | 220.00 Mn |
| Dec 31, 2024 | 222.00 Mn |
| Sep 30, 2024 | 220.00 Mn |
| Jun 30, 2024 | 222.00 Mn |
| Mar 31, 2024 | 277.00 Mn |
| Dec 31, 2023 | 271.00 Mn |
| Sep 30, 2023 | 259.00 Mn |
| Jun 30, 2023 | 278.00 Mn |
| Mar 31, 2023 | 216.00 Mn |
| Dec 31, 2022 | 258.00 Mn |
| Sep 30, 2022 | 241.00 Mn |
| Jun 30, 2022 | 250.00 Mn |
| Mar 31, 2022 | 241.00 Mn |
| Dec 31, 2021 | 257.00 Mn |
| Sep 30, 2021 | 259.00 Mn |
| Jun 30, 2021 | 261.00 Mn |